F. Hoffmann-La Roche Ltd. manufactures pharmaceutical products. It offers pharmaceutical drugs, pharmaceutical instruments, and diagnostics solutions. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland.

Genentech is a biotechnology company that discovers, develops, manufactures, and commercializes medicines to treat patients with serious or life-threatening medical conditions. It creates multiple products on the market and a development pipeline. The company became a member of the Roche Group in 2009. As part of their merger agreement, Roche and Genentech combined their pharmaceutical operations in the United States. Genentech’s South San Francisco campus now serves as the headquarters for Roche pharmaceutical operations in the United States. Genentech’s Research and Early Development section operates as an independent center within Roche. Genentech was founded in 1976 by [Robert Swanson](https://www.crunchbase.com/person/robert-a-swanson) and [Herbert Boyer](https://www.crunchbase.com/person/herbert-w-boyer). It is headquartered in South San Francisco, C.A.

Verastem, Inc. is a biopharmaceutical company, which engages in the development and commercialization of drugs for the treatment of cancer. The company was founded by Richard H. Aldrich, Michelle Dipp, Piyush Gupta, Satish Jindal, Eric S. Lander, Robert F. Weinberg, and Christoph H. Westphal on August 4, 2010 and is headquartered in Needham, MA.

Suzhou Mingrui Pharmaceutical Technology Co., Ltd., established on 2013-04-28, Business scope includes research and development:biomedicine(without lab),Health products;research and development,Sales:Pharmaceutical Intermediates,And provide related technology development,technical consulting,technology transfer,Technical Services,Engaged in the import and export business of the above commodities.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Hunan Eurasia Pharmaceutical Co., Ltd., established on 2007-11-22, Business scope includes chemical reagents and auxiliaries(Monitor Chemicals,Excluding hazardous chemicals)manufacturing,Sales;Manufacture of chemical raw materials;Production of disinfection products;Class I medical device,Class II medical device,Class III Medical Devices,Wholesale of chemical raw materials;Chemical Engineering Research Services;Chemical Products,Biological product,drug development;disinfectant,Sanitation products,Drug inspection and testing equipment sales.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Anqing Qichuang Pharmaceutical Co., Ltd., established on 2017-11-03, Business scope includes sales of hazardous chemicals(Operate according to the scope listed in the hazardous chemical business license);Pharmaceutical raw materials and intermediates(Free of chemical hazards),Fine Chemicals(Free of chemical hazards)research and development,Production,Sales and technical consultation,Technical Services,technology transfer;Import and export of goods or technology(Except for the import and export of goods and technologies that are prohibited by the state or involve administrative approval).(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Chengdu Pepsixing Technology Industry Co., Ltd., established on 2003-01-29, Business scope includes licensed projects:Food additive production;pharmaceutical production;Feed additive production;Pesticide production.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,The specific business items are subject to the approval documents or licenses of relevant departments)General project:Food Additive Sales;Manufacturing of medical packaging materials;Feed Additive Sales;Feed Raw Material Sales;Manufacturing of Specialty Chemical Products(Free of Hazardous Chemicals);Specialty Chemicals Sales(Free of Hazardous Chemicals);Chemical product production(No licensed chemical products);Manufacturing of basic chemical raw materials(Manufacture of licensed chemicals free of hazardous chemicals);Import and export;Technology Import and Export.(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)

Jining Medical University (simplified Chinese: 济宁医学院; traditional Chinese: 濟寧醫學院; pinyin: Jìníng Yīxuéyuàn), is a public institution of higher learning in Jining and Rizhao, Shandong province, China. It was founded in 1952 as Jining Medical Assistant School (济宁医士学校), in 1958 it became Jining Medical College (济宁医学院), and from 1959 to 1986 it was renamed as 济宁医学专科学校 (Jining Medical College, Three-Year MD program), and it was changed to its current name 济宁医学院 again (Jining Medical College, Five-Year MD program) in 1987. Most departments offer courses in different Medical sciences.

Harbin Medical University Pharmaceutical Co., Ltd., established on 1998-04-08, Business scope includes licensed projects:pharmaceutical production;Drug import and export;Pharmaceutical commissioned production;Disinfectant production(Free of Hazardous Chemicals);Production of hygiene products and single-use medical products;beverage production;food production;Production of tea products.General project:Production of Chinese herbal extracts;Medical Research and Experimental Development;Chinese herbal medicine acquisition;Purchase of primary agricultural products;Livestock acquisition;real estate herbal medicine(Does not contain Chinese herbal medicine)buy and sell;Aquatic product acquisition;Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Manufacturing of basic chemical raw materials(Manufacture of licensed chemicals free of hazardous chemicals).

Established in 1973 in Korea, Hanmi Pharmaceuticals now is one of the top 5 pharmaceutical companies in terms of revenue, and the most R&D focused company with the highest R&D investment for several years. Hanmi has been successful for a few decades with high flexibility, continuously changing its market/development strategy from first generics to IMD & FDC (Incrementally Modified Drug and Fixed Dose Combination) to new drug development including innovative small molecules and biologics. During the period of significant changes, Hanmi made multiple strategic collaboration relationships with multinational companies and biotech companies. Based on the success in 1980s and 1990s, Hanmi started its Chinese operation in 1996 with establishment of Beijing Hanmi. Now, Beijing Hanmi grew as a well-localized and well-settled Chinese company with more than 1,300 staffs including R&D, sales / marketing, and manufacturing experts and significant growth rate higher than 20% every year. Currently, Hanmi and Beijing Hanmi is closely collaborating on various business opportunities and new drug development projects as well as sales and marketing in Chinese territories. As the only Asian company with significant presence both in Korea and China, as the most R&D focused company with number of clinical stage projects with competitiveness, and as the company with open innovation based on multiple development/marketing collaborations, Hanmi is trying to develop and provide differentiated treatment options to patients suffering from various disease.

Shanghai Haoyuan Chemexpress Co. Ltd. engages in the research and development of related compounds in the development of new drugs. Its products include intermediate, vitamin D derivatives, and antibody drug conjugate (ADC). The company was founded by Bao Fu Zheng and Qiang Gao on September 30, 2006 and is headquartered in Shanghai, China.

The Board of Regents of The University of Texas System, a subsidiary of The University of Texas at Austin, is an American company located in Austin, TX. The firm oversees college activities.

Sandoz AG, a subsidiary of Novartis AG, is a company headquartered in Basel, Switzerland, that develops generic medicines and biosimilars.

The University of Iowa Research Foundation (UIRF) - a 501C3 corporation - commercializes University of Iowa developed technologies and inventions through licensing and new venture formation, and manages the subsequent revenue stream.

The legacy of Alembic Pharmaceuticals Limited (APL) dates back to over 100 years. Established in 1907 with an objective to develop and revolutionize the Pharmaceutical and Drug industry in the Indian subcontinent, Alembic Pharmaceuticals Limited today is one of the leading pharmaceutical companies in India. The publicly listed entity that manufactures and markets generic pharmaceutical products across the globe has grown by leaps and bounds over the last century. With an emphasis on innovation and technology, the company has established a state-of-the-art research facility – Alembic Research Centre (ARC)-including formulation research, and 150-bed bioequivalence facility at Vadodara, Gujarat. Additionally, APL has recently invested in ultra-modern R&D center at Hyderabad. APL is one of the leading players in the industry to have invested about 11% of its turnover in R&D. As a growth strategy, the company has aggressively started investing in the international generics market with successful ANDA and DMF filings. APL has also filings across Canada, Europe, Australia, South Africa & Brazil. The company caters to the rest of the world markets through branded formulation sales. The company aims to explore opportunities in the therapeutic areas such as Dermatology, Oncology, and Injectable Formulations. APL also has also co-promoted a company focused on discovery and development of innovative, small molecule drugs that target signal transduction networks and ion channels for the treatment of cancer, inflammation, autoimmune diseases and metabolic disorders.

Shanghai Haoyuan Biomedical Technology Co., Ltd., established on 2009-03-17, Business scope includes licensed projects:Hazardous Chemicals Management(see license).(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,The specific business items are subject to the approval documents or licenses of relevant departments) General project:Biomedical Technology,Technology development in the field of information technology,technical consulting,Technical Services,technology transfer,Biopharmaceutical Intermediates(In addition to drugs),Biological reagents for non-clinical diagnosis,Research and development of laboratory equipment and consumables,Sales,Business Management Consulting,Import and export,Technology Import and Export.(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)

CotheraBio develops innovative cancer therapies with a focus on translational oncology. It has developed its proprietary i-CR® technology platform, which is a powerful method for providing individualized drug screening and new drug development. The platform combines a high content screening system with the conditional reprogramming of primary cultured tumor cells, which enables the efficient and undifferentiated expansion of primary patient-derived tumor cells in vitro, while also preserving the tumor’s heterogeneity.